Researchers at UNC Lineberger and at other institutions developed a new potential treatment for acute myeloid leukemia. In the journal JCI Insight, they report that the compound MRX-2843 more than doubled the median days of survival in laboratory models with a drug-resistant form of the disease.
In the journal Cell Reports, UNC Lineberger researchers reported they found markedly low levels of the protein NLRX1 in multiple laboratory models of colorectal cancer, and in samples of human tissue. Studies have shown that the protein is known to be involved in regulating immune system signals in order to prevent hyperactive inflammatory responses by the immune system, but UNC Lineberger researchers believe their finding also points to a role for the protein in preventing colorectal cancer growth. Based on their findings, they believe they’ve identified a potential treatment for colorectal cancer with low NLRX1.
Kirsten Bryant, PhD, a cancer researcher and postdoctoral fellow at the UNC Lineberger Comprehensive Cancer Center, and Channing Der, PhD, a UNC Lineberger member and the Sarah Graham Kenan Professor of Pharmacology, shared personal stories of why they're driven to fight pancreatic cancer at a breakfast in Durham on Tuesday.
In a first-of-its-kind-study, researchers have discovered and applied a new screening technique capable of testing thousands of potential drug compounds to see if those compounds can reverse abnormal DNA unwinding in Ewing sarcoma, a bone and soft tissue cancer that’s most common in teens and young adults.